INDICATIONS AND USAGE（适应症）

MEKTOVI® is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

DOSAGE（服用剂量）

The recommended dosage of MEKTOVI is 45 mg orally taken twice daily, approximately 12 hours apart, in combination with encorafenib until disease progression or unacceptable toxicity. Refer to the encorafenib prescribing information for recommended encorafenib dosing information.

MEKTOVI may be taken with or without food. Do not take a missed dose of MEKTOVI within 6 hours of the next dose of MEKTOVI.

Do not take an additional dose if vomiting occurs after MEKTOVI administration but continue with the next scheduled dose.

ADVERSE REACTIONS（不良反应）

Cardiomyopathy

Venous Thromboembolism

Ocular Toxicities

Interstitial Lung Disease

Hepatotoxicity

Rhabdomyolysis

Hemorrhage

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/6c3408ac-d401-4925-8a03-26591afbc240/spl-doc?hl=Binimetinib

MEKTOVIinformation